Alberto M. Pedroncelli, MD, PhD

Chief Medical Officer
Camurus AB
Milan, ITALY

Disclosure information not submitted.

Presentation(s):

• MON-038 - Long-Term CAM2029 Octreotide Depot Maintains Biochemical and Symptom Control in Acromegaly Across A 4-Week Dosing Interval and during Intervals >28 Days: Data from the ACROINNOVA 2 Trial

  Monday, June 15, 2026
  9:00 AM - 2:00 PM CT